BGNE News and Press, BeiGene Ltd. From 12/03/23

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

2023-12-01 16:06:38 ET Summary Zymeworks Inc. showed positive results from the phase 1b/2 study using zanidatamab + chemotherapy + tislelizumab for the treatment of 1st-line HER2-positive G/GEJC. Results from the phase 3 HERIZON-GEA-01 study, using zanidatamab + chemotherapy + tis...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will host an Investor Event at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego and via webcast at 8:00 PM PST on December 10, 2023. This event w...

BRUKINSA ® (zanubrutinib) continues to show progression free survival (PFS) benefit compared with ibrutinib in extended follow-up of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) in the ALPINE trial Results of severa...

2023-11-26 02:40:00 ET Summary BeiGene acquires global rights to a preclinical CDK2 inhibitor from Ensem Therapeutics in a $1.3 billion agreement. Shanghai Usynova Biopharma out-licenses global rights for its KRASG12D inhibitor to AstraZeneca in a deal worth up to $419 million. ...

2023-11-24 20:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-21 12:49:08 ET More on BeiGene BeiGene: Staying On The Sidelines (Rating Downgrade) BeiGene inks $1.33B deal with Ensem Therapeutics for cancer drug BeiGene's Brukinsa gets Europe approval for follicular lymphoma Seeking Alpha’s Quant Rating on...

2023-11-21 07:11:07 ET More on BeiGene BeiGene: Staying On The Sidelines (Rating Downgrade) BeiGene's Brukinsa gets Europe approval for follicular lymphoma BeiGene regains full rights to cancer therapy from Novartis Seeking Alpha’s Quant Rating on BeiG...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and Ensem Therapeutics, Inc. (ENSEM), a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced an agreement for BeiGene to acquire an exclusive global license to a...

2023-11-17 07:35:11 ET More on BeiGene BeiGene: Staying On The Sidelines (Rating Downgrade) BeiGene regains full rights to cancer therapy from Novartis Seeking Alpha’s Quant Rating on BeiGene Historical earnings data for BeiGene Financial infor...